

RNS Number : 4446Y
Genus PLC
26 February 2025

For Immediate Release

26 February 2025

**Genus plc
('Genus', or the 'Company')**

Non-Executive Director Retirement

Genus (LSE: GNS), a leading global animal genetics company, announces that Professor Jason Chin has informed the Company of his intention to step down from the Genus Board, effective from the end of May 2025, as he will be taking on a significant new role as Founding Director of the Generative Biology Institute at the Ellison Institute of Technology. Professor Chin has served as a Non-Executive Director, Chairman of the Company's Scientific Advisory Board and advisor to the Company's Global Portfolio Steering Committee for four years. Upon stepping down from the Board, Professor Chin will remain a member of the Scientific Advisory Board.

The Board has initiated a comprehensive search for Professor Chin's successor and will provide an update once this process has concluded.

Commenting on the changes, Iain Ferguson, Chairman of Genus, said:

"Over the last four years Professor Jason Chin has provided the Company with significant scientific expertise, guidance and insight as we progress our innovative science platforms. We wish him well in his new role."

Genus

Tel: +44(0)1256 345970

Iain Ferguson, Chairman

Jorgen Kokke, Chief Executive

Burson Buchanan

Tel: +44(0)207 466 5000

Charles Ryland; Toto Berger; Sophie Wills; Verity
Parker

This announcement is available on the Genus website www.genusplc.com

About Genus

Genus is a world-leading animal genetics company. Genus creates advances to animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.

Genus's worldwide sales are made in over seventy-five countries under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and breeding animals with superior genetics to those animals currently in farms. Genus's customers' animals produce offspring with greater production efficiency, and quality, and use these to supply the global dairy and meat supply chains.

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network.

With headquarters in Basingstoke, United Kingdom, Genus companies operate in over twenty-five countries on six continents, with research laboratories located in Madison, Wisconsin, USA.

Regulatory Notes

This announcement is made in accordance with Listing Rule 6.4.6R. The person responsible for making this announcement on behalf of the Group is Vaughn Walton (Interim Company Secretary).

Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOAPPUPUPUPAGBA